For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for British American Tobacco p.l.c. (BTI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +2 (−100…+100 Quality+Value blend) · Quality 5 · Value -1 · Sentiment -22 (timing only, not weighted) · Composite fair value $60.24 vs $58.73 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
British American Tobacco p.l.c.
BTI NYSEBritish American Tobacco p.l.c. ADR represents American depositary shares of British American Tobacco p.l.c., a global multi-category consumer goods company focused on tobacco and nicotine products. The business today spans traditional combustible cigarettes, roll-your-own and other tobacco products, as well as newer categories such as vapour products, tobacco-heating devices, and modern oral nicotine offerings. Its portfolio includes a wide range of international and local brands distributed across the United States, the Americas and Europe, and the Asia-Pacific, Middle East and Africa regions. British American Tobacco p.l.c. ADR provides U.S.-based investors with economic exposure to the London-headquartered parent company through securities that mirror ownership of its ordinary shares. The company plays a significant role in the global consumer staples and tobacco industry, supplying products to adult consumers and operating across diverse regulatory and market environments. Founded in 1902 and headquartered in London, United Kingdom, British American Tobacco p.l.c. remains a major presence in worldwide tobacco and nicotine markets.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
This company does not file structured financial statements with the U.S. SEC, so quarterly figures aren't available from our filings-based data engine. Annual figures shown here come from the sources that do cover it.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 4.70
Total Equity: $64.76B
Shares: 2,199,000,000
Total Debt: $47.17B
Cash: $5.15B
EBITDA: $16.87B
Total Debt: $47.17B
Cash: $5.15B
Revenue: $34.45B
Revenue: $34.45B
Revenue: $34.45B
Total Equity: $64.76B
Tax Rate: 21.2%
Equity: $64.76B
Total Debt: $47.17B
Cash: $5.15B
Current Liabilities: $19.54B
Long-Term Debt: $42.65B
Total Debt: $47.17B
Total Equity: $64.76B
Shares: 2,199,000,000
Shares: 2,199,000,000
CapEx: -$741.16M
Shares: 2,199,000,000
Stock Price: $58.69
Net Income: $10.44B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 5, 2026 9:37am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $34.5B | $37.2B | $36.7B | $34.8B | $34.4B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | — | — | — | — | — |
| Operating Income | $13.8B | $14.2B | -$21.2B | $3.7B | $13.4B |
| Net Income | $9.1B | $9.0B | -$19.3B | $4.1B | $10.4B |
| EBITDA | $15.2B | $15.9B | $17.3B | $7.9B | $16.9B |
| EPS | $3.99 | $3.95 | $-8.70 | $1.84 | $4.72 |
| EPS (Diluted) | $3.98 | $3.93 | $-8.70 | $1.83 | $4.70 |
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:37am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.8B | $4.6B | $6.3B | $7.1B | $5.1B |
| Total Current Assets | $17.2B | $20.7B | $19.1B | $19.2B | $17.1B |
| Total Assets | $184.8B | $206.5B | $159.7B | $159.9B | $147.0B |
| Current Liabilities | $20.4B | $24.0B | $21.1B | $25.2B | $19.5B |
| Long-Term Debt | $48.0B | $52.1B | $47.6B | $43.9B | $42.7B |
| Total Liabilities | $94.1B | $104.7B | $88.5B | $92.7B | $82.2B |
| Total Equity | $90.7B | $101.8B | $71.2B | $67.2B | $64.8B |
| Retained Earnings | $59.5B | $59.3B | $33.0B | $29.1B | $30.8B |
Cash Flow (Annual)
Last updated: Aug 5, 2026 9:37am (18d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $13.1B | $14.0B | $14.4B | $13.6B | $8.5B |
| Capital Expenditure | -$708.9M | -$703.5M | -$618.8M | -$653.7M | -$741.2M |
| Free Cash Flow | $12.4B | $13.3B | $13.8B | $13.0B | $7.8B |
| Acquisitions (net) | — | — | — | — | — |
| Net Debt Issued / (Repaid) | -$5.2B | $300.0M | -$2.2B | -$3.3B | -$158.7M |
| Dividends Paid | -$6.7B | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$571.7M | $1.2B | $1.6B | $789.6M | -$1.8B |
Growth Trends (YoY %)
Last updated: Aug 5, 2026 9:37am (18d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +7.7% | -1.3% | -5.2% | -1.0% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | +2.8% | -249.7% | +117.4% | +265.4% |
| Net Income Growth | -2.0% | -315.5% | +121.4% | +153.1% |
| EBITDA Growth | +4.6% | +8.8% | -54.6% | +114.9% |
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:37am (18d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-07-10 | $0.84 | — | — | — |
| 2026-03-27 | $0.84 | — | — | — |
| 2025-12-30 | $0.75 | — | — | — |
| 2025-10-03 | $0.75 | — | — | — |
| 2025-06-27 | $0.75 | — | — | — |
| 2025-03-28 | $0.75 | — | — | — |
| 2024-12-20 | $0.74 | — | — | — |
| 2024-09-27 | $0.74 | — | — | — |
| 2024-06-28 | $0.74 | — | — | — |
| 2024-03-21 | $0.74 | — | — | — |
| 2023-12-21 | $0.70 | — | — | — |
| 2023-09-28 | $0.70 | — | — | — |
| 2023-07-13 | $0.70 | — | — | — |
| 2023-03-23 | $0.72 | — | — | — |
| 2022-12-22 | $0.67 | — | — | — |
| 2022-09-29 | $0.64 | — | — | — |
| 2022-07-07 | $0.66 | — | — | — |
| 2022-03-24 | $0.68 | — | — | — |
| 2021-12-22 | $0.73 | — | — | — |
| 2021-09-30 | $0.72 | — | — | — |
Deep Analysis
Narrative Economics
market-narrative step).
Claude Reading
The raw numbers tell a simpler story than the models suggest. Revenue has done nothing for five years — $34.55B in 2021, $34.45B in 2025, with a peak of $37.2B in 2022. That's not "structural decline," it's stagnation with FX noise. The 2023 -$21.19B operating loss is a non-cash impairment on US combustibles brand intangibles (Reynolds writedown), not an operating event, so the 2024 "recovery" to $3.68B op income is optically misleading — and the 2025 snap-back to $13.45B op / $10.44B NI is the real underlying run-rate. On that basis, 39% operating margin and 30% net margin are intact, ROE 16%, and FCF of $7.79B against a $127.8B market cap is a ~6.1% FCF yield supporting the 5.4% dividend with room. Net debt of $42B against $13.5B operating income is ~3.1x — elevated but manageable for a tobacco cash machine, and trending down.
Where I diverge from the synthesis: the composite fair value of $60-62 feels anchored to backward-looking multiples on a business whose reported earnings just got scrambled by a goodwill impairment cycle. Strip the 2023 writedown noise and the underlying earnings power is closer to $10B/yr sustainably, putting normalized P/E near 12x on a business with pricing power, oligopoly structure, and — critically — a smoke-free category (Velo, Vuse, glo) that is now roughly 17-18% of revenue and approaching profitability. PM trades at ~22x and Altria at ~11x; BTI at 12.5x is priced closer to Altria's US-concentrated decline story than to PM's global reduced-risk optionality, despite BTI having the #2 global vapor position by revenue. That's the mispricing the bull narrative points at, and I think it's real, though smaller than bulls claim.
The contrarian pushback is the FCF trajectory: -24.9% FCF CAGR is not a rounding error. Operating cash flow of $8.53B on $10.44B net income is a 82% conversion ratio — fine but not the historical 100%+ tobacco investors expect, suggesting working capital drag or cash taxes catching up. If FCF truly compresses toward $6B, the dividend (~$5B annual cost) covers but doesn't leave room for meaningful deleveraging or NGP reinvestment simultaneously. The bear case isn't "tobacco apocalypse" — it's that BTI is stuck funding a dividend, servicing debt, AND trying to out-invest PM in modern oral/heated tobacco with insufficient cash. That's a capital allocation squeeze, not a demand collapse, and it's the reason the discount to PM persists. Also, the insider "activity" listed is share conversion/award noise from the UK dual-listing structure — the "Net Insider Buying" secondary signal is essentially meaningless here. The models should not have flagged that as bullish.
The market forces model failed outright and the pre-flight thesis about "meaningful dividend sustainability risk" is overstated — a 5.4% yield with ~65% FCF payout at current run-rate is not a distressed dividend. The narrative model's "fallen-angel/moderate discount" read is the most honest of the bunch. My verdict: I partially agree with the synthesis direction (modestly undervalued) but think the magnitude is bigger than +6% if you normalize through the impairment cycle and give any credit to smoke-free reaching profitability by 2026 as management guides. Fair value on 13-14x normalized earnings of ~$4.80/ADR is $62-67, plus you're paid 5.4% to wait. The risk is regulatory (FDA menthol, EU flavor bans on vapor) and a genuine FCF stall, not extinction. This is a starter-position-and-collect-dividends stock at $58.69, not a table-pounder — the upside is 10-15% plus yield, capped by the fact that terminal value in tobacco is genuinely uncertain past 10 years.
GPT Reading
BTI still looks like what the rule-based model says it is — a mature earner — but the valuation output feels a touch too forgiving about the quality of that “earnings.” The core numerical story is not growth; it is resilience bought through pricing, cost control, and balance-sheet management in a shrinking top line. Revenue has drifted from $37.20B in 2022 to $36.70B in 2023, $34.79B in 2024, and $34.45B in 2025, a roughly 3% annual contraction over the period. That would be fine if cash conversion were holding steady, but 2025 operating cash flow of $8.53B and free cash flow of $7.79B are meaningfully lower than what many BTI investors implicitly underwrite when they treat this as a bond proxy. The reported 2025 net margin of 30.3% and operating margin of 39.0% look excellent, yet they sit next to a very recent history of a $21.19B operating loss and $19.33B net loss in 2023, which tells you normalized profitability is heavily influenced by non-trivial accounting swings, not just smooth annuity-like economics. At 12.5x earnings and 10.1x EV/EBITDA, this is not expensive in absolute terms, but it is not distressed either for a business with negative revenue CAGR and sharply negative FCF CAGR.
The balance sheet is manageable, not pristine. BTI has $47.17B of debt against $5.15B of cash, so net debt is roughly $42B. Against 2025 operating income of $13.45B, that is serviceable; against operating cash flow of $8.53B, it is more constraining than the equity story usually admits. Debt-to-equity of 0.73 looks acceptable on paper, but equity itself is flattered by the recovery from 2023’s impairment-heavy year; tobacco investors should care more about hard cash generation than accounting equity. The current ratio below 0.9 is normal enough for a consumer staple with dependable inflows, but it reinforces that this is a highly optimized capital structure, not a fortress. The dividend yield of 5.4% is attractive and appears covered by 2025 free cash flow, yet not by a huge margin once you consider refinancing costs, FX, litigation, and the need to fund reduced-risk products. For a company priced at nearly 3.75x sales despite persistent revenue shrinkage, the market is already giving considerable credit for durability.
What stands out most is the tension between the rebound in reported earnings and the weaker cash trajectory. Net income jumped from $4.13B in 2024 to $10.44B in 2025, but revenue fell and operating cash flow is only $8.53B. That is a yellow flag for anyone leaning too hard on the P/E. If 2025 is the “normal” year, then BTI earns its multiple and maybe deserves low-single-digit upside. But if 2025 is simply the optical bounce after a writedown-distorted 2023 and depressed 2024, then the stock is closer to fully valued than cheap. I do not see evidence here of a business turning back into a grower; I see a very profitable decline franchise whose valuation support comes from yield and scarcity of dependable cash generators, not from improving fundamentals. That makes the slight-upside model output directionally plausible but too neat: a 6% discount to fair value is trivial when the underlying cash stream is drifting down.
The best counterargument is straightforward and serious: a business earning $10.44B of net income, $7.79B of free cash flow, 16.1% ROE, and 9.9% ROIC while yielding 5.4% should not trade at only 12.5x earnings unless the market is over-penalizing secular decline. In that framing, 2023 was a one-off impairment year, 2024 was transitional, and 2025 shows the normalized economics are still excellent. Revenue only slipped 1% most recently, which is much less alarming than the long-term anti-tobacco narrative implies, and if reduced-risk categories can stabilize the top line, even modestly, the stock could rerate toward the low-to-mid teens earnings multiple without heroic assumptions. I weigh that argument less heavily because the revenue line has not actually stabilized over several years, and because the cash flow trend matters more than a recovered EPS figure for a leveraged dividend stock. A cheap multiple on repaired accounting earnings is not enough if the enterprise is slowly consuming its own strategic flexibility.
What would change my mind is evidence that the 2025 recovery is cash-real and durable rather than optical. If BTI can print at least two consecutive years of free cash flow above $8.5B-$9.0B while holding revenue roughly flat around $34B-$35B and taking net debt down by at least $3B-$5B cumulatively, I would be more constructive and willing to pay into the low $60s. Conversely, if revenue continues to slip 2%-3% annually and operating cash flow stays around the current $8.5B level or lower while the dividend remains the dominant use of capital, then the current price is already generous for a melting-ice-cube franchise. The key test is not whether BTI can report another high-margin earnings year; it is whether it can prove that declining combustibles can still fund both the dividend and deleveraging without further erosion in the cash base.
Grok Reading
The raw numbers tell a story of a high-margin franchise grinding through a controlled descent rather than a collapse. Revenue has slipped from $37.20B in 2022 to $34.45B in 2025, a clean -3.1% CAGR that matches the secular volume bleed in combustibles; yet 2025 operating profit snapped back to $13.45B and net income to $10.44B, restoring the 39% operating margin and 30% net margin that defined the pre-impairment years. The 2023 -$19.33B loss and still-soft 2024 print were accounting events (goodwill and related charges), not evidence that the underlying cash engine seized. Free cash flow of $7.79B on only $741M of capex remains formidable, equating to a 6.1% FCF yield at the $127.8B enterprise, and the $47.17B debt load sits against $64.76B of equity with a manageable 0.73 D/E. At 12.5x trailing earnings, 10.1x EV/EBITDA and a 5.4% dividend that is covered 1.1x by FCF, the market is simply refusing to pay for durability.
What stands out is how little reinvestment is required to keep the machine running and how completely the valuation ignores the margin recovery. ROE of 16% and ROIC near 10% on a declining top line are the signature of a pricing-power oligopoly harvesting cash; the balance-sheet current ratio of 0.87 is tight but not alarming for a business with this predictability. The insider tape is noise—conversions and awards, not directional buying—so the “net buying” flag can be discarded. Relative to the prior models’ $62.40 fair-value composite, the stock at $58.69 sits only a few percent below, yet that modest gap understates the asymmetry once normalized earnings are accepted as the base rather than the impairment-distorted mid-cycle.
The strongest counter-argument is the free-cash-flow trajectory. A -24.9% FCF CAGR is not noise; it implies that either working-capital absorption, higher cash taxes, or rising interest on the $47B debt stack is eroding conversion faster than revenue is falling. If that pace continues, the 5.4% dividend becomes a payout ratio problem within two to three years, exactly the “dividend trap” the bear narrative describes. BTI’s next-generation portfolio still lags PMI’s heated-tobacco scale, so the market’s 20-turn multiple gap is rational rather than emotional. Elevated leverage also leaves limited room for a mis-step on refinancing or an adverse regulatory shock in the US or UK. These points justify a permanent discount; they do not, however, justify treating 2025’s restored $10.4B of earnings as a one-off when the operating margin has simply returned to its multi-year mean.
I would reverse to a clear overvalued stance if next-twelve-month FCF falls below $6.5B or if the dividend is cut; conversely, two consecutive quarters of NGP revenue growth above 15% combined with net-debt reduction below $38B would push me to a high-conviction undervalued call above $70.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
BTI is a mature cash machine: FCF ran $12.4B, $13.3B, $13.8B, $13.0B and $7.79B across 2021-2025, with OCF/NI at 1.27x and accruals at -6.1% of assets — earnings are cash-backed, not manufactured. Revenue is flat-to-declining ($34.55B to $34.45B over five years), which is on-brand for tobacco, and the 2023 net loss of $19.33B reflects a large non-cash impairment (US combustibles brand writedown) rather than a cash event, evidenced by FCF actually rising that year to $13.79B. Diluted shares have been quietly walked down at -1.1% CAGR (2.30B to 2.20B), so per-share economics compound even without top-line growth. Management/entity activity shows conversions and awards rather than open-market P-code buying, so the 'insider buying' framing is weak.
Verify before trusting this (6)
- Nature and drivers of the 2025 FCF drop to $7.79B from ~$13B - working capital, tax, or underlying?
- Debt maturity ladder and average coupon against the $42B net debt position
- Trajectory of New Categories (vapor/heated/modern oral) revenue and profitability vs combustibles
- Details of the 2023 US combustibles brand impairment and whether further writedowns are likely
- Whether the May 2026 conversions/awards involve any real cash outlay by executives, or purely equity-plan mechanics
- Dividend policy sustainability and payout ratio against the lower 2025 FCF base
The e2e synthesis lands at a composite fair value of $60.24 and signal-adjusted $62.40 against a $58.73 price - a 3-6% gap that is well inside model noise. The DCF at $84.78 and anchored P/E at $77.65 both point higher, but they are offset by an EPV floor of -$6.24, which reflects the market's real fear: that combustibles run off before next-gen scales. That negative EPV is a loud signal that steady-state earning power on today's declining core is not what it looks like on a trailing multiple.
Verify before trusting this (5)
- Next-gen category profitability trajectory (Vuse, Velo, glo) - is it truly self-funding yet?
- Combustibles volume decline rate in US and emerging markets vs price/mix offset
- Net debt trajectory and dividend coverage from FCF, not accounting earnings
- Any further brand impairments or write-downs in upcoming filings
- Regulatory moves on menthol, nicotine caps, and flavored vape
BTI sits almost entirely outside the market's mood swings — beta 0.13 means the mildly risk-on tape and the +46 regime score barely register here. What actually presses on this name is the fallen-angel narrative around tobacco: moderate intensity, moderate durability, low cult, meaning the story is a persistent drag but not an acute one. The 8%+ yield anchors income buyers, and the pouch/next-gen nicotine pivot has a live catalyst as PM doubles down on ZYN capacity — a headline that cuts both ways (validates the category, spotlights BTI as the follower). Analyst tone is not screaming either direction and target revisions are absent from the brief. Momentum is quietly negative (-3.1% CAGR, weakening cash generation flagged), which reinforces the slow-bleed narrative even if the 3y print is fine. Net: no dominant force. The macro headwinds bucket (4.63% 10y, 27.7 market PE) is a mild negative for a bond-proxy yielder, but tobacco's regulated-oligopoly cash flow keeps sentiment from cratering. Balanced pressure with a faint headwind tilt from the narrative and rates, offset by yield-hunt bid and low market sensitivity.
Verify before trusting this (4)
- Any BAT-specific pouch/Velo volume or capacity announcement to counter the PM/ZYN narrative
- Analyst target revisions post-interim results and dividend coverage commentary
- 10y yield trajectory - a break lower would meaningfully re-rate high-yield defensives
- FDA/regulatory news flow on menthol or vape category that could jolt sentiment either way
This lens hasn't been run for this ticker yet.
When we made this prediction on Aug 7, 2026, BTI was $58.73. We expect it to be $63.50 by Feb 2027, and we consider it great value under $50.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 7, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.